Next Article in Journal
Synthesis and Preliminary Evaluation of N-Oxide Derivatives for the Prevention of Atherothrombotic Events
Previous Article in Journal
Antibacterial Activity, Antioxidant Effect and Chemical Composition of Propolis from the Región del Maule, Central Chile
Previous Article in Special Issue
Special Issue—Towards Understanding the Mechanisms and Curing of Muscular Dystrophy Diseases
Article Menu

Export Article

Open AccessReview
Molecules 2015, 20(10), 18168-18184;

Duchenne Muscular Dystrophy: From Diagnosis to Therapy

Unit of Medical Genetics, Department of Medical Sciences, University of Ferrara, Ferrara, 44121 Italy
Bambino Gesù Hospital, Rome, 00146, Italy
Authors to whom correspondence should be addressed.
Academic Editor: Leonidas A. Phylactou
Received: 20 July 2015 / Revised: 15 September 2015 / Accepted: 28 September 2015 / Published: 7 October 2015
Full-Text   |   PDF [1086 KB, uploaded 7 October 2015]   |  


Duchenne muscular dystrophy (DMD) is an X-linked inherited neuromuscular disorder due to mutations in the dystrophin gene. It is characterized by progressive muscle weakness and wasting due to the absence of dystrophin protein that causes degeneration of skeletal and cardiac muscle. The molecular diagnostic of DMD involves a deletions/duplications analysis performed by quantitative technique such as microarray-based comparative genomic hybridization (array-CGH), Multiple Ligation Probe Assay MLPA. Since traditional methods for detection of point mutations and other sequence variants require high cost and are time consuming, especially for a large gene like dystrophin, the use of next-generation sequencing (NGS) has become a useful tool available for clinical diagnosis. The dystrophin gene is large and finely regulated in terms of tissue expression, and RNA processing and editing includes a variety of fine tuned processes. At present, there are no effective treatments and the steroids are the only fully approved drugs used in DMD therapy able to slow disease progression. In the last years, an increasing variety of strategies have been studied as a possible therapeutic approach aimed to restore dystrophin production and to preserve muscle mass, ameliorating the DMD phenotype. RNA is the most studied target for the development of clinical strategies and Antisense Oligonucleotides (AONs) are the most used molecules for RNA modulation. The identification of delivery system to enhance the efficacy and to reduce the toxicity of AON is the main purpose in this area and nanomaterials are a very promising model as DNA/RNA molecules vectors. Dystrophinopathies therefore represent a pivotal field of investigation, which has opened novel avenues in molecular biology, medical genetics and novel therapeutic options. View Full-Text
Keywords: dystrophin; molecular diagnosis; Antisense Oligonucleotides; antisense delivery; DMD therapy dystrophin; molecular diagnosis; Antisense Oligonucleotides; antisense delivery; DMD therapy

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Falzarano, M.S.; Scotton, C.; Passarelli, C.; Ferlini, A. Duchenne Muscular Dystrophy: From Diagnosis to Therapy. Molecules 2015, 20, 18168-18184.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top